Article Text

Download PDFPDF
Case report
Extragastrointestinal stromal tumour (EGIST) presented as a mesenteric and retroperitoneal mass
  1. Carlos Costa Almeida1,
  2. Teresa Vieira Caroço2,
  3. Miguel Albano1 and
  4. Luís Carvalho1
  1. 1 General Surgery, Hospital Geral (Covões), Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal
  2. 2 General Surgery, Instituto Portugues de Oncologia de Coimbra Francisco Gentil EPE, Coimbra, Portugal
  1. Correspondence to Dr Carlos Costa Almeida; carloscostaalmeida{at}


Extragastrointestinal stromal tumour (EGIST) occurs outside the gastrointestinal tract and has histopathological and molecular characteristics similar to gastrointestinal stromal tumour (GIST). This tumour is rare and aggressive. A male patient was admitted with anaemia and lower limb oedema. CT scan showed a tumour in the mesentery and retroperitoneum, suspected to be a small bowel GIST. During laparotomy an unresectable mass was found compressing the retroperitoneal structures. Pathology and immunohistochemistry (CD117) confirmed an EGIST. EGIST arises from Cajal-like cells or from pluripotent stem cells outside the gastrointestinal tract. It is aggressive and has a worse prognosis than GIST. Immunohistochemistry is crucial for diagnosis. Surgery aimed at debulking as much of a tumour mass as possible is the cornerstone of treatment. The role of imatinib is not clear. EGIST is rare and has a bad prognosis, and there is no consensus on grading and management. A low threshold of suspicion is crucial for early diagnosis.

  • general surgery
  • surgical oncology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors CCA: data collection, writing, review. TVC: writing, review. MA, LC: review.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Next of kin consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.